Samsung Bioepis’ Etanercept Nod Prompts US Lawsuit
Executive Summary
The FDA has approved Samsung Bioepis’ Eticovo as the second biosimilar competitor to Amgen’s blockbuster rheumatoid arthritis biologic Enbrel. Amgen immediately sued for patent infringement.